Skip to main content
. 2022 Feb 24;14(5):1164. doi: 10.3390/cancers14051164

Figure 2.

Figure 2

Analysis of FLT3 expression in AML patients. (A) Transcript levels of FLT3 in AML patients versus control patients. (B) Percent survival of high-FLT3-expressing patients versus low-FLT3-expressing AML patients. The hazard ratio is 1.8, and the p-value is 0.035, as analyzed from the TCGA dataset upon GEPIA analysis.